Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial

Bailey T. S.; Takacs R.; Tinahones F. J.; Rao P. V.; Tsoukas G. M.; Thomsen A. B.; Kaltoft M. S.; Maislos M.

首页> 外文期刊>Diabetes, obesity & metabolism >Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial

【24h】

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial

机译：从西他列汀转用利拉鲁肽治疗2型糖尿病（LIRA-SWITCH）的有效性和安全性：一项随机，双盲，双模拟，主动控制的26周试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimsTo confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8mg/d versus continued sitagliptin.

机译：目的通过与连续西他列汀相比，从西他列汀改为利拉鲁肽1.8mg / d来证实其在血糖控制方面的优越性。

著录项

来源
《Diabetes, obesity & metabolism》 |2016年第12期|共8页
作者
Bailey T. S.; Takacs R.; Tinahones F. J.; Rao P. V.; Tsoukas G. M.; Thomsen A. B.; Kaltoft M. S.; Maislos M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词
liraglutide; sitagliptin; type 2 diabetes; GLP-1 receptor agonist;

机译：利拉鲁肽;西他列汀;2型糖尿病;GLP-1受体激动剂;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial [J] . Bailey T. S., Takacs R., Tinahones F. J., Diabetes, obesity & metabolism . 2016,第12期

机译：从西他列汀转用利拉鲁肽治疗2型糖尿病（LIRA-SWITCH）的有效性和安全性：一项随机，双盲，双模拟，主动控制的26周试验
2. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin [J] . AhrénB., JohnsonS.L., StewartM., Diabetes care . 2014,第8期

机译：和谐3：一项104周的随机，双盲，安慰剂和活性对照试验评估了阿比鲁肽与安慰剂，西他列汀和格列美脲相比在服用二甲双胍的2型糖尿病患者中的有效性和安全性
3. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes a randomized, open-label trial [J] . PratleyR.E., NauckM.A., BaileyT., Diabetes care . 2012,第10期

机译：在二甲双胍治疗的2型糖尿病患者中，在52周后从DPP-4抑制剂西他列汀转换为人GLP-1类似物利拉鲁肽的疗效和安全性是一项随机，开放标签试验
4. A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL TO INVESTIGATE THE EFFICACY OF TIAMULIN IN THE CONTROL OF PORCINE PROLIFERATIVE ENTEROPATHY (PPE) AND PORCINE COLONIC SPIROCHAETOSIS (PCS) UNDER FIELD CONDITIONS [C] . J. Haugegaard, K. Moller, T.K. Jensen, Congress of the International Pig Veterinary Society . 2000

机译：一种双盲随机安慰剂对照临床试验，探讨硫霉素在野生植物中猪增殖肠病（PPE）和猪结肠螺旋肌肤症（PCS）的疗效
5. A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Effect of Infliximab on General Cognition in a Population of Depressed Individuals with Bipolar Disorder Type I/II [D] . Pan, Zihang. 2018

机译：一项随机，双盲，安慰剂对照的临床试验，评估英夫利昔单抗对I / II型双相情感障碍抑郁症患者总体认知的影响
6. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA‐SWITCH): a randomized double‐blind double‐dummy active‐controlled 26‐week trial [O] . T. S. Bailey, R. Takács, F. J. Tinahones, -1

机译：从西他列汀转为利拉鲁肽治疗2型糖尿病（LIRA-SWITCH）的有效性和安全性：一项随机双盲双模拟主动控制的26周试验
7. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial [O] . T. S. Bailey, R. Takács, F. J. Tinahones, 2016

机译：在2型糖尿病（Lira-Switch）的受试者中从SitaGliptin切换到Liraglutide的疗效和安全性（Lira-Switch）：随机，双盲，双伪，有效控制的26周试验

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial

摘要

著录项

相似文献

相关主题

期刊订阅